Lucien Hordijk (1988) has been covering the pharmaceutical industry for six years, reporting on skyrocketing prices, regulatory capture, generic shortages, biosimilars and industry lobbying. His investigations led to national publications and international coverage in the Financial Times, The Wall Street Journal and Reuters.
The patent on the cancer drug Revlimid (lenalidomide) recently expired. Whereas a few weeks ago a pack still cost over 4,500 euros, after generic competition
By Lucien Hordijk and Daan Marselis Using a set of legal tricks, the pharmaceutical industry was able to turn an animal gallic acid into a
Leaked documents show that the European Commission put pressure on the European Medicines Agency to approve the first Covid-19 vaccines simultaneously with the American FDA.
The drug’s manufacturer was aware of the negative results of the Solidarity trial before the European Commission struck a procurement deal with it, finds an
By Lucien Hordijk & Daan Marselis Most of the demand for (refresher) training courses for doctors in the Netherlands is fulfilled by industry- sponsored programmes.
Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in
Even after the expiration of Humira’s patent protection, AbbVie, the pharmaceutical company, almost completely fended off biosimilar competition for this blockbuster medicine in the Netherlands.
By Lucien Hordijk Steve Jobs’ private plane, parked at Rotterdam Airport. It is September 2008 when local reporters receive tips about the arrival of Apple’s
The Investigative Desk is an independent platform for investigative journalism, focusing on large international industrial sectors such as defence & security, energy, food, pharmaceuticals & health care, and tobacco.
Read more